|
|
4041 Forest Park Avenue
St. Louis, MO 63108 USA
phone:(314) 615-6340
fax:(314) 615-6901
|
|
| Symbol |
Private |
| Founded |
2006 |
| Employees |
|
|
|
| www.medrospharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drug development through Drosphilia and modeling. |
|
| Management |
| Robert Karr, M.D., President; Kenneth Janoski, Chairman; Thomas Baranski, M.D.,Ph.D. Co-Founder; Ross Cagan, Ph.D.- Co-Founder |
| |
|
|
| |
|
| Keywords |
| cancer, Diabetes, blood sugar, diabetic, metabolic, insulin, stl |
|
|
|
| Description |
|
Medros utilizes the Drosophila to take whole animal approach to drug discovery for cancer metastasis and for diabetes-related diseases. Medros seeks to procure drug libraries and screen them with its proprietary models to identify lead compounds for cancer and diabetes indications. |
|
| Technology / Differentiation |
| Medros utilizes Drosophila to take a novel, whole animal approach to drug discovery for cancer metastasis and for diabetes-related diseases. The company is founded on the scientifically validated premise that traditional methods of gene discovery neglect the complex tissue and cell interactions that occur in the context of a whole animal. The whole animal approach embraces disease complexity to improve the prospects for better efficacy with lower risk for toxicity. |
|
|
| Strategy |
Medros has established short- and long-term business strategies that are designed to leverage the promise of its proprietary platforms while remaining focused on achievable goals. A central goal of Medros is to demonstrate that our Drosophila screening platform reduces the cost of drug discovery, increases its speed, and improves overall outcomes through the clinic. As part of this validation Medros is focused on the cancer and diabetes markets due to their potential to yield drugs with sales in excess of $1 billion. To this end, Medros is working to identify novel compounds in both areas that (i) show promising efficacy, (ii) minimal or acceptable levels of toxicity, and for which (iii) Medros will have maximal composition of matter protection.
|
|
| Funding |
| Medros has received funding from BioGenerator ($500,000) and from SBIR and STTR grants ($446,000); two additional SBIRs will be funded shortly based on their strong scores (~$500,000) and additional grants have been submitted. The company intends to raise approximately $7 million Series A to fund advancement of the cancer and diabetes projects, while continuing discussions with pharmaceutical companies about partnerships. |
|
| Status |
| Medros has exclusive license from Washington University for the screening platform. Medros has exclusive license to two patents filed in the U.S. and worldwide; these patents cover both the proprietary screening platform and Drosophila-based disease models. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members